| 期刊論文| 1. | Patel, Y.C.(1999)。Somatostatin and its receptor family。Front Neuroendocrinol，20，157-198。   | | 2. | Schuppan, D.、Afdhal, N.H.(2008)。Liver cirrhosi。Lancet，371，838-851。 | | 3. | Sharara, A.I .、Rockey, D.C.(2001)。Gastroesophageal variceal hemorrhage。N Engl J Med，345，669-681。 | | 4. | Dib, N.、Oberti, F.、Calès, P.(2006)。Current management of the complications of portal hypertension: variceal bleeding and ascites。CMAJ，174，1433-1443。 | | 5. | Garcia-Tsao, G.(2005)。Portal hypertension。Curr Opin Gastroenterol，21，313-322。 | | 6. | Fabrizi, F.、Dixit, V.、Martin, P.(2006)。Meta-analysis: terlipressin therapy for the hepatorenal syndrome。Aliment Pharmacol Ther，24，935-944。 | | 7. | Bañares, R .、Albillos, A .、Rincón, D .(2002)。Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis。Hepatology，35，609-615。 | | 8. | Calès, P .、Masliah, C .、Bernard, B .、Garnier, P.P .、Silvain, C .、Szostak-Talbodec, N. et al.(2001)。Early administration of vapreotide for variceal bleeding in patients with cirrhosis。N Engl J Med，344，23-28。 | | 9. | Gralnek, I.M .、Jensen, D.M.(1997)。Cost assessments in the management of variceal bleeding。Clin Liver Dis，1，45-58。 | | 10. | D'Amico, G.、De Franchis, R.(2003)。Cooperative Study Group. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators.。Hepatology，38，599-612。 | | 11. | Wu, C.Y .、Yeh, H.Z .、Chen, G.H.(2002)。Pharmacologic efficacy in gastric variceal rebleeding and survival: including multivariate analysis。J Clin Gastroenterol，35，127-132。 | | 12. | Boyd, R.、Butler, J.(2005)。Best evidence topic report. Terlipressin or somatostatin for the treatment of bleeding oesophageal varices.。Emerg Med J，22，433-434。 | | 13. | Walker, S.、Kreichgauer, H.P.、Bode, J.C.(1992)。Terlipressin vs. somatostatin in bleeding esophageal varices: a controlled, double-blind study.。Hepatology，15，1023-1030。 | | 14. | Feu, F.、Ruiz del Arbol, L.、Bañares, R.、Planas, R.、Bosch, J.(1996)。Double-blind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage.。Variceal Bleeding Study Group. Gastroenterology，111，1291-1299。 | | 15. | Mnatzaganian, G .、Sprung, C.L .、Zitser-Gurevich, Y .、Galai, N .、Goldschmidt, N .、Levi, L. et al.(2008)。Effect of infections on 30-day mortality among critically ill patients hospitalized in and out of the intensive care unit.。Crit Care Med，36，1097-1104。 | | 16. | Suljagic, V .、Cobeljic, M .、Jankovic, S .、Mirovic, V .、Markovic-Denic, L .、Romic, P. et al.(2005)。Nosocomial bloodstream infections in ICU and non-ICU patients。Am J Infect Control，33，333-340。 | | 17. | Williams, M.T.、Aravindan, N.、Wallace, M.J.、Riedel, B.J .、Shaw, A.D.(2003)。Venous thromboembolism in the intensive care unit。Crit Care Clin，19，185-207。 | | 18. | Cook, D.J.、Fuller, H.D.、Guyatt, G.H.、Marshall, J.C.、Leasa, D.、Hall, R. et al.(1994)。Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group。N Engl J Med，330，377-381。 | | 19. | Laupland, K.B.、Zygun, D.A.、Davies, H.D.、Church, D.L.、Louie, T.J.、Doig, C. J.(2002)。Populationbased assessment of intensive care unitacquired bloodstream infections in adults: Incidence, risk factors, and associated mortality rate。Crit Care Med，30，2462-2467。 | | 20. | Vosylius, S.、Sipylaite, J.、Ivaskevicius, J.(2003)。Intensive care unit acquired infection: a prevalence and impact on morbidity and mortality。Acta Anaesthesiol Scand，47，1132-1137。 | | 21. | Roubenoff, R .、Harris, T.B.、Abad, L.W .、Wilson, P.W .、Dallal, G.E .、Dinarello, C.A.(1998)。Monocyte cytokine production in an elderly population: effect of age and inflammation。J Gerontol A Biol Sci Med Sci,，53，20-26。 | | 22. | Girón-González, J.A.、Martínez-Sierra, C.、Rodriguez-Ramos, C.、Macías, M.A.、Rendón, P .、Díaz, F. et al.(2004)。Implication of inflammationrelated cytokines in the natural history of liver cirrhosis.。Liver Int,，24，437-445。 | | 23. | Boden, G .、Vaidyula, V .、Homko, C .、Mozzoli, M .、Rao, A.K.(2007)。Differential effects of somatostatin on circulating tissue factor procoagulant activity and protein.。Am J Physiol Endocrinol Metab，292，1333-1339。 | | 24. | Reubi, J.C .、Krenning, E .、Lamberts, S.W .、Kvols, L.(1990)。Somatostatin receptors in malignant tissues。J Steroid Biochem Mol Biol，37，1073-1077。 | | 25. | Weckbecker, G .、Raulf, F .、Stolz, B .、Bruns, C.(1993)。Somatostatin analogs for diagnosis and treatment of cancer.。Pharmacol Ther.,，60，245-264。 | | 26. | Reubi, J.C .、Laissue, J .、Krenning, E .、Lamberts, S.W.(1992)。Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications。J Steroid Biochem Mol Biol.，43，27-35。 | | 27. | Dimitroulopoulos, D .、Xinopoulos, D .、Tsamakidis, K .、Zisimopoulos, A .、Andriotis, E .、Panagiotakos, D. et al.(2007)。Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebocontrolled trial。World J Gastroenterol.，13，3164-3170。 | | 28. | Kouroumalis, E .、Skordilis, P .、Thermos, K .、Vasilaki, A .、Moschandrea, J .、Manousos, O.N.(1998)。Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study.。Gut.,，42，442-447。 | | 29. | Dagher, L .、Patch, D .、Marley, R .、Moore, K .、Burroughs, A.(2000)。Review article: pharmacological treatment of the hepatorenal syndrome in cirrhotic patients.。Aliment Pharmacol Ther.,，14，515-521。 | |
| |